JP2015508812A - 非自己免疫性糖尿病を抑制および処置するためのｈｓｐ６０由来ペプチドおよびペプチド類似体 - Google Patents

非自己免疫性糖尿病を抑制および処置するためのｈｓｐ６０由来ペプチドおよびペプチド類似体 Download PDF

Info

Publication number
JP2015508812A
JP2015508812A JP2014559346A JP2014559346A JP2015508812A JP 2015508812 A JP2015508812 A JP 2015508812A JP 2014559346 A JP2014559346 A JP 2014559346A JP 2014559346 A JP2014559346 A JP 2014559346A JP 2015508812 A JP2015508812 A JP 2015508812A
Authority
JP
Japan
Prior art keywords
val
leu
ala
hsp60
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014559346A
Other languages
English (en)
Japanese (ja)
Inventor
コーエン，イラン，アール．
マルガリット，ラーナン
Original Assignee
イエダ リサーチ アンド ディベロプメント カンパニー リミテッド
イエダ リサーチ アンド ディベロプメント カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イエダ リサーチ アンド ディベロプメント カンパニー リミテッド, イエダ リサーチ アンド ディベロプメント カンパニー リミテッド filed Critical イエダ リサーチ アンド ディベロプメント カンパニー リミテッド
Publication of JP2015508812A publication Critical patent/JP2015508812A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014559346A 2012-03-01 2013-02-28 非自己免疫性糖尿病を抑制および処置するためのｈｓｐ６０由来ペプチドおよびペプチド類似体 Pending JP2015508812A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605262P 2012-03-01 2012-03-01
US61/605,262 2012-03-01
PCT/IL2013/050174 WO2013128450A1 (en) 2012-03-01 2013-02-28 Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

Publications (1)

Publication Number Publication Date
JP2015508812A true JP2015508812A (ja) 2015-03-23

Family

ID=48050870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014559346A Pending JP2015508812A (ja) 2012-03-01 2013-02-28 非自己免疫性糖尿病を抑制および処置するためのｈｓｐ６０由来ペプチドおよびペプチド類似体

Country Status (8)

Country Link
US (1) US20150018271A1 (enExample)
EP (1) EP2819692A1 (enExample)
JP (1) JP2015508812A (enExample)
CN (1) CN104244967A (enExample)
AU (1) AU2013227249A1 (enExample)
CA (1) CA2864655A1 (enExample)
IN (1) IN2014MN01887A (enExample)
WO (1) WO2013128450A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114945585A (zh) * 2019-11-18 2022-08-26 卫理公会系统医院 用于心力衰竭的纳米疫苗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5780034A (en) 1989-03-14 1998-07-14 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
US5578303A (en) 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
WO1996019236A1 (en) 1994-12-21 1996-06-27 Yeda Research And Development Co. Ltd. PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
IL114407A0 (en) 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
AU2003209623A1 (en) 2002-02-19 2003-09-09 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
WO2005072056A2 (en) 2004-01-28 2005-08-11 Develogen Israel Ltd. Hsp therapy in conjunction with a low antigenicity diet
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
WO2007046834A2 (en) * 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
WO2006096565A2 (en) * 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
IN2014MN01887A (enExample) 2015-07-10
CN104244967A (zh) 2014-12-24
WO2013128450A1 (en) 2013-09-06
EP2819692A1 (en) 2015-01-07
CA2864655A1 (en) 2013-09-06
AU2013227249A1 (en) 2014-09-11
US20150018271A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
US20240082361A1 (en) Methods and compositions for treating hypoglycemic disorders
CN102389413A (zh) 用于治疗糖尿病的组合物及其应用
EP0944396A1 (en) Compositions and methods for enhancing intestinal function
US8828922B2 (en) HSP therapy in conjunction with a low antigenicity diet
US20090202494A1 (en) Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20160271221A1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
ES2253353T3 (es) Reduccion del colesterol serico.
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
US20140322213A1 (en) Pharmaceutical Composition for the Treatment of Type-1 Diabetes
JP2017517561A (ja) 最適化ハムスターｒｅｇ３ガンマペプチドを利用する糖尿病を有する患者の間でのインスリン非依存性
JP2015508812A (ja) 非自己免疫性糖尿病を抑制および処置するためのｈｓｐ６０由来ペプチドおよびペプチド類似体
US20150011471A1 (en) Regeneration of islet beta cells by hsp60 derived peptides
US20250059248A1 (en) Il-4 derived peptides for use in the treatment of obesity
WO2024189056A1 (en) Annexin a1 administration regime
KR102627084B1 (ko) 대사성 질환을 치료하기 위한 조성물 및 방법
EP3402505B1 (en) Pharmaceutical formulations for the treatment of diabetes
US20200054716A1 (en) Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies
HUP9901774A2 (hu) II Típusú kollagént tartalmazó gyógyszerkészítmények reumaszerű ízületi gyulladás kezelésére